Keyword: Johnson & Johnson

FDA Commissioner Scott Gottlieb has turned to an unusual tactic to tackle drug pricing through generics competition.

Doctors who got free meals, speaking fees and other payments from drugmakers also prescribed more opioids, a new analysis found.

In many ways, 2017 was a "wait-and-see" year for biopharma. But things are picking up speed in 2018.

Johnson & Johnson’s Darzalex just vaulted ahead of its myeloma competitors—and it has plenty of them.

Portola has won FDA approval of Andexxa, its antidote for some next-gen bloodthinners, but a manufacturing upgrade will limit initial supplies.

Ahead of a big launch this fall, Biogen says it plans to increase its stake in a biosimilars joint venture shared with Samsung.

Pfizer stumbled at the FDA with its biosimilar application for a product that would challenge Roche's breast cancer stalwart Herceptin.

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.